17:12 ET Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
I'm PortAI, I can summarize articles.
Kahn Swick & Foti, LLC is investigating the proposed sale of Astria Therapeutics, Inc. (ATXS) to BioCryst Pharmaceuticals, Inc. (BCRX). Shareholders are set to receive $8.55 in cash and 0.59 shares of BioCryst stock for each share of Astria. The firm aims to determine if this offer adequately values the company. Interested parties can contact KSF for more information regarding their legal rights related to the sale.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: prnewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments